Perceptive Advisors Llc Buys Iovance Biotherapeutics Inc, Zymeworks Inc, Regeneron Pharmaceuticals Inc, Sells Amarin Corp PLC, Momenta Pharmaceuticals Inc, Foamix Pharmaceuticals

• New Purchases: REGN, ALLO, TBPH, MNLO, DNLI, PODD, GILD, LPTX, SDGR, ATRC, SILK, MYL, MEIP, ONEM, XLRN, CUE, CCXI, TARA, APLS,
• Added Positions: IOVA, ZYME, NVRO, COLL, DBVT, GBT, MRTX, AGRX, MYOK, ADPT, KDMN, BPMC, ALBO, SWTX, VCRA, TWST, ISEE, RVNC, HCAT, PRVB,
• Reduced Positions: NBIX, MNTA, BIO, ZGNX, ARNA, ANAB, TPTX, RGNX, ESTA, YMAB, RCKT, VAPO, EIDX, UROV, AXNX,
• Sold Out: AMRN, FOMX, EHTH, TNDM, ARVN, AUPH, ICPT, NVTA, ACST, ARWR, SWAV, CRY, DRNA, KPTI, NVCR, DCPH, SIC, ARAV, NTRA, OPTN, CNST, ACAD, PRTO,

For the details of PERCEPTIVE ADVISORS LLC's stock buys and sells, go to https://www.gurufocus.com/guru/perceptive+advisors+llc/current-portfolio/portfolio

1. Iovance Biotherapeutics Inc (IOVA) - 11,670,057 shares, 9.54% of the total portfolio. Shares added by 23.94%
2. Global Blood Therapeutics Inc (GBT) - 6,065,726 shares, 8.47% of the total portfolio. Shares added by 3.41%
3. Neurocrine Biosciences Inc (NBIX) - 3,063,263 shares, 7.24% of the total portfolio. Shares reduced by 15.21%
4. Mirati Therapeutics Inc (MRTX) - 3,319,450 shares, 6.97% of the total portfolio. Shares added by 3.62%
5. Amicus Therapeutics Inc (FOLD) - 25,182,364 shares, 6.36% of the total portfolio. Shares added by 0.20%

Perceptive Advisors Llc initiated holding in Regeneron Pharmaceuticals Inc. The purchase prices were between $336.18 and $494.43, with an estimated average price of $411.31. The stock is now traded at around $576.72. The impact to a portfolio due to this purchase was 1.07%. The holding were 80,000 shares as of .

Perceptive Advisors Llc initiated holding in Allogene Therapeutics Inc. The purchase prices were between $18.22 and $28.25, with an estimated average price of $23.87. The stock is now traded at around $44.91. The impact to a portfolio due to this purchase was 0.82%. The holding were 1,543,790 shares as of .

Perceptive Advisors Llc initiated holding in Theravance Biopharma Inc. The purchase prices were between $17.84 and $31.21, with an estimated average price of $25.05. The stock is now traded at around $27.41. The impact to a portfolio due to this purchase was 0.63%. The holding were 1,000,000 shares as of .

Perceptive Advisors Llc initiated holding in Menlo Therapeutics Inc. The purchase prices were between $2.18 and $6.94, with an estimated average price of $4.41. The stock is now traded at around $1.69. The impact to a portfolio due to this purchase was 0.48%. The holding were 6,637,179 shares as of .

Perceptive Advisors Llc initiated holding in Denali Therapeutics Inc. The purchase prices were between $14.2 and $27.98, with an estimated average price of $20.9. The stock is now traded at around $22.65. The impact to a portfolio due to this purchase was 0.41%. The holding were 850,000 shares as of .

Perceptive Advisors Llc initiated holding in Insulet Corp. The purchase prices were between $130.01 and $216.44, with an estimated average price of $183.11. The stock is now traded at around $203.98. The impact to a portfolio due to this purchase was 0.37%. The holding were 82,733 shares as of .

Perceptive Advisors Llc added to a holding in Iovance Biotherapeutics Inc by 23.94%. The purchase prices were between $19.54 and $38.85, with an estimated average price of $26.44. The stock is now traded at around $36.28. The impact to a portfolio due to this purchase was 1.84%. The holding were 11,670,057 shares as of .

Perceptive Advisors Llc added to a holding in Zymeworks Inc by 48.19%. The purchase prices were between $24.28 and $49.8, with an estimated average price of $41.23. The stock is now traded at around $37.49. The impact to a portfolio due to this purchase was 1.12%. The holding were 3,560,999 shares as of .

Perceptive Advisors Llc added to a holding in Nevro Corp by 42.96%. The purchase prices were between $70.23 and $144.31, with an estimated average price of $120.56. The stock is now traded at around $117.66. The impact to a portfolio due to this purchase was 0.88%. The holding were 1,092,068 shares as of .

Perceptive Advisors Llc added to a holding in Collegium Pharmaceutical Inc by 268.34%. The purchase prices were between $13.89 and $25.45, with an estimated average price of $20.72. The stock is now traded at around $22.03. The impact to a portfolio due to this purchase was 0.5%. The holding were 1,551,722 shares as of .

Perceptive Advisors Llc added to a holding in DBV Technologies SA by 67.54%. The purchase prices were between $2.33 and $12.98, with an estimated average price of $9.06. The stock is now traded at around $5.33. The impact to a portfolio due to this purchase was 0.31%. The holding were 7,317,809 shares as of .

Perceptive Advisors Llc added to a holding in Agile Therapeutics Inc by 33.55%. The purchase prices were between $1.58 and $4.4, with an estimated average price of $2.88. The stock is now traded at around $2.59. The impact to a portfolio due to this purchase was 0.2%. The holding were 15,919,325 shares as of .

Perceptive Advisors Llc sold out a holding in Amarin Corp PLC. The sale prices were between $4 and $21.53, with an estimated average price of $16.75.

Perceptive Advisors Llc sold out a holding in Foamix Pharmaceuticals Ltd. The sale prices were between $2.99 and $4.71, with an estimated average price of $3.99.

Perceptive Advisors Llc sold out a holding in eHealth Inc. The sale prices were between $85.7 and $146.09, with an estimated average price of $114.23.

Perceptive Advisors Llc sold out a holding in Tandem Diabetes Care Inc. The sale prices were between $47.37 and $90.04, with an estimated average price of $70.13.

Perceptive Advisors Llc sold out a holding in Arvinas Inc. The sale prices were between $33 and $54.5, with an estimated average price of $46.8.

Perceptive Advisors Llc sold out a holding in Aurinia Pharmaceuticals Inc. The sale prices were between $11.34 and $21.46, with an estimated average price of $17.73.

Perceptive Advisors Llc reduced to a holding in Momenta Pharmaceuticals Inc by 98.92%. The sale prices were between $18.96 and $33.96, with an estimated average price of $27.82. The stock is now traded at around $31.09. The impact to a portfolio due to this sale was -1.14%. Perceptive Advisors Llc still held 30,637 shares as of .

Perceptive Advisors Llc reduced to a holding in Bio-Rad Laboratories Inc by 94.91%. The sale prices were between $320.01 and $409.07, with an estimated average price of $368.41. The stock is now traded at around $466.72. The impact to a portfolio due to this sale was -0.49%. Perceptive Advisors Llc still held 3,489 shares as of .

Perceptive Advisors Llc reduced to a holding in Arena Pharmaceuticals Inc by 29.17%. The sale prices were between $34.83 and $54.15, with an estimated average price of $45.98. The stock is now traded at around $47.26. The impact to a portfolio due to this sale was -0.26%. Perceptive Advisors Llc still held 675,129 shares as of .

Perceptive Advisors Llc reduced to a holding in AnaptysBio Inc by 50%. The sale prices were between $12.82 and $18.69, with an estimated average price of $15.2. The stock is now traded at around $18.82. The impact to a portfolio due to this sale was -0.17%. Perceptive Advisors Llc still held 500,000 shares as of .

Perceptive Advisors Llc reduced to a holding in Turning Point Therapeutics Inc by 20.01%. The sale prices were between $32.02 and $66.17, with an estimated average price of $53.48. The stock is now traded at around $64.21. The impact to a portfolio due to this sale was -0.11%. Perceptive Advisors Llc still held 349,890 shares as of .